\u3000\u3000
Science and Technology Daily reporter Jiang Yun
“In the past year, the State Drug Administration approved more than 20 domestic innovative drugs to be listed, a new high in recent three years. The number of innovative drugs approved to be listed is gradually approaching that of the United States, and many innovative drugs have approached or reached the international advanced level.” Ding lieming, deputy to the National People’s Congress and chairman of Betta Pharmaceuticals Co.Ltd(300558) board, believes that from the perspective of research and development, China’s new drug research and development has experienced the stages of “tracking imitation” and “imitation innovation”, and has entered a new stage of original innovation.
What needs to be faced with is that since the R & D of innovative drugs in China started late and the starting point is not high enough, China should further optimize the scientific and technological innovation ecology, increase support, promote collaborative innovation, and encourage multiple parties to jointly promote the independent R & D of new drugs.
In this regard, Ding lieming put forward four suggestions: actively explore the rational pricing mechanism of innovative drugs dominated by clinical value and win-win; Further enhance the coordination between relevant institutions and experts in clinical R & D; Attract more overseas high-end talents and speed up the cultivation of leading talents and innovation teams in new drug R & D; Further increase tax incentives for biomedical venture capital funds.
